Maximizing the Survival of Amyotrophic Lateral Sclerosis Patients: Current Perspectives by Osama A. Khairoalsindi, Ahmad R. Abuzinadah

“…The disease has a poor prognosis, with only two disease-modifying drugs approved by the United States Food and Drug Administration (FDA). The approved drugs for the disease have very limited survival benefits. …”
Get full text

IS IT POSSIBLE TO USE BEVACIZUMAB BIOSIMILAR IN ALL INDICATIONS REGISTERED FOR ORIGINAL DRUG? by S. V. Orlov, N. L. Shimanovskii, S. N. Fogt

“…Currently, the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) have identified specific conditions under which for biosimilars extrapolation of indications is possible. …”
Get full text

Sugammadex-Associated Hypotension, Bradycardia, Asystole, and Death by Kazim Mirza, Kathryn Landoski, Dilip Thakar, Jagtar Heir-Singh, Timothy Jackson, Cynthia Kassab

“…On December 16, 2015, the Food and Drug Administration (FDA) in the United States approved sugammadex (Bridion, Merck and Co), a modified gamma-cyclodextrin, to be used as a reversal agent. …”
Get full text

Progress in Managing Heart Failure: an in-depth Review of Sacubitril/Valsartan Combination Therapy by Neeraj Hiremath, Jayasheela S. Hiremath, Sanatkumar B. Nyamagoud, Agadi Hiremath Viswanatha Swamy

“…The United States Food and Drug Administration has approved the drug’s use in treating patients with chronic heart failure with reduced ejection fraction (HFrEF). …”
Get full text

Pharma TARP: A Troubled Asset Relief Program for Novel, Abandoned Projects in the Pharmaceutical Industry by Tamas Bartfai, Graham Vaughan Lees

“…The authors propose a radical response by the U.S. government and the National Institutes of Health to rescue these abandoned projects, and to continue selected programs for drug approval by the U.S. Food and Drug Administration and the European Medicines Agency. …”
Get full text

Author Correction: Yindanxinnaotong, a Chinese compound medicine, synergistically attenuates atherosclerosis progress by Long Cheng, Guo-feng Pan, Xiao-dong Zhang, Jian-lu Wang, Wan-dan Wang, Jian-yong Zhang, Hui Wang, Ri-xin Liang, Xiao-bo Sun

Get full text

Effects of Cosmetic Formulations Containing Hydroxyacids on Sun-Exposed Skin: Current Applications and Future Developments by Andrija Kornhauser, Sergio G. Coelho, Vincent J. Hearing

Get full text

New Onset Tinnitus after High-Frequency Spinal Cord Stimulator Implantation by Alexander V. Golovlev, Michael G. Hillegass

“…To further explore these less common neurologic complications of SCS therapy, a review of literature and a review of the U.S. Food and Drug Administration Manufacturer and User Facility Device Experience database are included. …”
Get full text

Fibromyalgia: do I tackle you with pharmacological treatments? by Serge Perrot

“…Globally, pharmacological approaches are weakly effective but market authorization differs between Europe and United States. Food and Drug Administration–approved medications for fibromyalgia treatment include serotonin and noradrenaline reuptake inhibitors, such as duloxetine, and pregabalin (an anticonvulsant), which target neurotransmitter modulation and central sensitization. …”
Get full text

Ipilimumab: A First-in-Class  T-Cell Potentiator for Metastatic Melanoma by Bartosz Chmielowski

“…In 2011, ipilimumab (3 mg/kg every 3 weeks for 4 doses) was approved by the Food and Drug Administration for unresectable or metastatic melanoma. …”
Get full text

Incidental Discovery of Hepatocellular Carcinoma on 18F-PSMA PET CT Performed for Prostate Cancer Reassessment by Lauren Hekman, Eva Napierkowski, Natalie C. Hartman, Jeffrey L. Ellis, Robert H. Wagner, Davide Bova, Maria M. Picken, Robert C. Flanigan

“…Prostate-specific membrane antigen positron emission tomography (PSMA PET) has been approved by the Food and Drug Administration (FDA) to identify prostate cancer in the setting of biochemical recurrence but can also identify other malignancies. 18F-PSMA PET has not been studied as a potential tool for hepatocellular carcinoma (HCC). …”
Get full text

In Vitro Activities of Ceftobiprole and Doripenem Tested against Frequently Encountered Aerobic and Facultative Gram-Positive and Gram-Negative Bacterial Pathogens Isolated from Pa... by James A Karlowsky, Mel DeCorby, Daryl J Hoban, George G Zhanel

“…BACKGROUND: In 2008, ceftobiprole was approved by Health Canada for the treatment of patients with complicated skin and skin structure infections including diabetic foot infections; approval of ceftobiprole by the United States Food and Drug Administration is pending. Doripenem is currently under review by Health Canada and was approved by the United States Food and Drug Administration in 2007 for the treatment of patients with complicated intra-abdominal infections and complicated urinary tract infections, including pyelonephritis. …”
Get full text

Is Exploration of Alternate Immune Pathways Needed in Hidradenitis Suppurativa? A Case of Atopic Dermatitis and Concurrent Hidradenitis Suppurativa Responding to Dupilumab by Sean McCormack, Noor Tazudeen, Benjamin C. Garden

“…Only one such biologic, adalimumab, has been approved by the US Food and Drug Administration (FDA) for the treatment of HS. Other such biologics currently being studied for HS downregulate Th1/Th17 inflammatory pathways. …”
Get full text

Neurological Crisis Following Intravenous Ozone Therapy; a Case Report by Chloe Y Y Wong, Komal Saxena, John Meneer, Koshy George, Gerben Keijzers

“…Despite claims of therapeutic benefits, Regulatory agencies, such as the U.S. Food and Drug Administration (FDA), warn against its use due to its toxic properties and lack of proven benefits at tolerable exposure levels. …”
Get full text

Anti-Amyloid Imaging Abnormality in the Era of Anti-Amyloid Beta Monoclonal Antibodies: Recent Updates for the Radiologist by So Yeong Jeong, Chong Hyun Suh, Jae-Sung Lim, Yangsean Choi, Ho Sung Kim, Sang Joon Kim, Jae-Hong Lee

“…Lecanemab and donanemab have received full U.S. Food and Drug Administration (FDA) approval, and subsequently, lecanemab has been approved by the Korean FDA and it has recently entered commercial use in Korea. …”
Get full text

Probiotics and Alcoholic Liver Disease: Treatment and Potential Mechanisms by Fengyuan Li, Kangmin Duan, Cuiling Wang, Craig McClain, Wenke Feng

“…Although many agents and approaches have been tested in patients with ALD and in animals with experimental ALD in the past, there is still no FDA (Food and Drug Administration) approved therapy for any stage of ALD. …”
Get full text

Biomarkers of traumatic brain injury. Literature review by A. Šmigelskytė, M. Remenčiūtė, V. Ragaišis

“…In the year of 2018, the US Food and Drug Administration approved a combination of GFAP and UCH-L1. …”
Get full text

Clinical Biology and Potential Use of Thrombopoietin by Russell Basser

“…However, one of these agents, interleukin-11, was successfully shown to reduce the incidence of severe thrombocytopenia in patients receiving dose-intensive chemotherapy, and has now received approval from the United States Food and Drug Administration for this purpose. Initial clinical trials of thrombopoietin, the central regulator of megakaryocytopoiesis and thrombopoiesis, and its analogues showed these agents to be the most potent stimulators of thrombopoiesis and to be associated with few adverse effects. …”
Get full text

Preventing Foodborne Illness: E. coli “The Big Six” by Susanna Richardson, Renée M. Goodrich-Schneider, Keith R. Schneider

“…In addition to E. coli O157:H7, the U.S. Food and Drug Administration has identified six serogroups (or “strains”), known as the “big six,” which includes E. coli O26, O45, O103, O111, O121, and O145. …”
Get full text

An Interference Avoidance Method of Wireless Body Area Network Based on Chinese Medical Band by Weixia Zou, Chao Guo, Fengyuan Kang, Chunqing Zhang

Get full text